Last $144.09 USD
Change Today +6.58 / 4.79%
Volume 9.0M
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/21/14 - $145.49
52 Week Low
04/28/14 - $108.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Announces the Appointment of R. Sanders Williams to Board of Directors

Amgen announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor. Dr. Williams will serve on the Corporate Responsibility and Compliance Committee and the Governance and Nominating Committee of the Board. Following the appointment of Dr. Williams, the Board on October 17, 2014, will comprise 13 directors, 12 of whom are independent. Dr. Williams currently serves as the President of Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, both since 2010. He is also a Professor of Medicine at the University of California, San Francisco since 2010.

Amgen Declares Fourth Quarter Cash Dividend, Payable on December 5, 2014

Amgen announced that its board of directors declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend will be paid on December 5, 2014, to all stockholders of record as of the close of business on November 13, 2014.

Amgen Announces Positive Results from Phase 3 Study Evaluating the Efficacy and Safety of Biosimilar Candidate ABP 501

Amgen announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira(R) (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint. The primary endpoint was the Psoriasis Area and Severity Index (PASI) % improvement from baseline to week 16 of treatment. At week 16, the PASI % improvement from baseline was within the prespecified equivalence margin for ABP 501 compared to adalimumab. Safety and immunogenicity of ABP 501 were comparable to adalimumab. This is the first of two Phase 3 studies intended to form the basis for global regulatory submissions for ABP 501. ABP 501 is being developed as a biosimilar to adalimumab, an anti-TNF- monoclonal antibody, which is approved in many countries for the treatment of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis (PsO), polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $144.09 USD +6.58

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $140.93 USD +3.33
AbbVie Inc $56.29 USD +1.88
Bristol-Myers Squibb Co $51.95 USD +1.39
Eli Lilly & Co $64.68 USD +1.58
Novo Nordisk A/S kr263.70 DKK +2.90
View Industry Companies

Industry Analysis


Industry Average

Valuation AMGN Industry Range
Price/Earnings 20.5x
Price/Sales 5.2x
Price/Book 4.2x
Price/Cash Flow 20.3x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at